Guangzhou Innogen Pharm Grp Co (2591) Fair Value & Analysis
Healthcare · HK · Market cap HK$3.6B
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 3 days ago
Share price −23.3% over the past month.
Below-average quality, and screening another 68% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$2.61). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (HK$1.38 to HK$2.61) leaves room in how you read the outcome.
Price vs Fair Value (12 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
12‑month range HK$6.61 – HK$57.25 · fair‑value band HK$1.38 – HK$2.61 · the HK$6.61 price screens above the HK$2.09 fair value. As of Aug 13, 2026.
Analysis
Guangzhou Innogen Pharm Grp Co (2591) currently trades at HK$6.61, while our model-based Fair Value estimate is HK$2.09, implying the stock looks roughly 68.4% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at HK$132M. It earns a return on equity of -36.9%. The balance sheet holds a net cash position of HK$803M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$1.38 (bear case) to HK$2.61 (bull case); at HK$6.61, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -68%, 2591 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 2591 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 0
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases.
Full company description
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Guangzhou Innogen Pharm Grp Co reported revenue of HK$128M in FY2025 versus HK$0 in FY2023. Reported net income was −HK$333M in FY2025.
2591 screens 68% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 605 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
Compare Guangzhou Innogen Pharm Grp Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Guangzhou Innogen Pharm Grp Co (2591) overvalued or undervalued?
What is the fair value of 2591?
What is the quality score of 2591?
What is the revenue of Guangzhou Innogen Pharm Grp Co (2591)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Guangzhou Innogen Pharm Grp Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.